CLINICAL_TRIALS
trial_result
· 2015-05-21
Clinical Trial Update: Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years [Phase 3]
Summary
Phase 3 safety study of FSME-IMMUN NEW in healthy children and adolescents aged 1 to 15 years completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Tick-borne Encephalitis | Phase 3 | Status: COMPLETED